What I Saw at a GE Aviation Parts Plant Changed How I Think About Batch Records

The first thing I noticed walking into the GE Aviation Advanced Manufacturing facility in Cincinnati was that there were no pallets of raw material stacked three stories high. In their place: a row of eight industrial additive manufacturing systems running 24 hours a day, feeding finished parts directly into assembly lines. This is not a pilot program. This is production scale, validated, and running under quality protocols that would make a pharma quality director nod in recognition.

I spent four hours on the plant floor last week documenting how additive manufacturing has moved past prototyping and entered the regulated manufacturing space. What I found matters to anyone running a bioreactor facility or managing sterile fill operations. The validation framework GE Aviation built for 3D-printed metal components parallels exactly what pharmaceutical manufacturing will need when this technology moves into drug product assembly and primary packaging.

The critical moment came when I reviewed their batch records. Every part printed on these systems is tracked through a digital twin that logs layer thickness, material composition, thermal profiles, and structural verification. The system feeds directly into their manufacturing execution system. No hand-written deviations. No retroactive documentation. When I asked the plant manager whether they had considered FDA 21 CFR Part 11 compliance during the design phase, she smiled and said it was built in from day one, not bolted on later. That distinction matters. Parts printed in January are still under traceability surveillance in April.

Here is what changed my thinking: additive manufacturing does not eliminate regulatory documentation. It transforms it. Traditional subtractive manufacturing generates waste streams and creates geometric limitations that require post-processing steps. Each step is a control point, each a separate batch record entry. Additive manufacturing consolidates those steps into a single, digitally logged process. From a quality perspective, that is either a nightmare if your IT infrastructure is weak, or a competitive advantage if you have built the digital backbone first.

The facility runs under aerospace equivalent specifications, which means materials are certified to AS9100D standards and design validation follows MIL-SPEC requirements. The comparison to pharmaceutical manufacturing is direct: both industries require material certificates of analysis, process validation across the intended operating range, and long-term stability data. The only difference is the timeline. Aerospace needs engines that function reliably for 20 years under extreme conditions. Pharma needs the same from a bioreactor system, a freeze-dryer, or a manufacturing suite.

What an operations director should take from this: the validation playbook for additive manufacturing in regulated environments already exists. It is being executed at production volume right now. The bottleneck for pharmaceutical adoption is not technical. It is organizational. The companies that move first will be those that build additive manufacturing qualification into their digital infrastructure before they install the first system on the production floor.

Three companies I cannot yet name are running pilot programs with additive manufacturing for pharmaceutical equipment housings and component assemblies. One has FDA pre-submission meeting documentation dated Q2 2026. The precedent is being set this quarter. If your organization is not already evaluating the technology path, you are waiting for a competitor to validate it first.